The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000672358
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
20/03/2026
Date registered
Help: Date registered
5/06/2026
Date last updated
Help: Date last updated
5/06/2026
Date data sharing statement initially provided
Help: Data sharing statement date
5/06/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Combined Use of Ginger and Vitamin B6 to prevent chemotherapy induced nausea and vomiting (CINV)
Scientific title
Pilot Study Evaluating Ginger and Vitamin B6 for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderate- to High-Emetogenic Risk Regimens in an Oncology Day Unit: A pre-post intervention analysis.
Additional trial identifiers [1] 316831 0
Nil Known
Universal Trial Number (UTN)
U1111-1337-7054
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Nausea 341193 0
Vomiting 341197 0
Cancer 341518 0
Condition category
Condition code
Cancer 337285 337285 0 0
Any cancer

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Prospective, single-arm, pre-post intervention pilot study starting from first cycle of chemotherapy and continue for subsequent cycles, if tolerated.
1. Pre-Intervention Phase (Cycle 1 – without ginger/vitamin B6):
Only patients who experience any episode(s) of nausea and/or vomiting during cycle 1 —regardless of whether breakthrough anti-emetic medications are used—will proceed to the intervention phase.
2. Intervention Phase (Cycle 2 onwards – with ginger/vitamin B6):
Eligible patients will receive the ginger and vitamin B6 supplementation in addition to standard anti-emetic care. . [From Cycle 2 onwards to maximum of 12 treatment cycles or whichever comes first *]
3. Post-Intervention Assessment:
Outcomes will be assessed through patient surveys and the MASCC (Multinational association of supportive care in cancer) Antiemesis Tool (MAT) to compare pre- and post-intervention results.

Medications used for this trial are as follows:

The intervention consists of a single compounded capsule (administered twice daily - morning and night) containing:

Dry Ginger powder: 125mg [Total maximum daily dose = 250mg]
Pyridoxal-5'-Phosphate (P-5-P), equivalent to Vitamin B6: 12.5mg Pyridoxine hydrochloride [Total maximum daily dose = 25mg]
Doxylamine 6.25mg (6.25mg (optional at night-time dose): To be included in the compounded capsule only as determined by the treating doctor

• Continuing for 5 days after chemotherapy (Days 2-6) of each cycle from Cycle 2 onwards as outlined in study procedure phase.

• If a dose is missed at the usual time, skip the dose and take the dose when it is next due- Do NOT double dose.

**Labelling: If Doxylamine is included in the capsule, it must be clearly labelled with dosing instructions and timing (e.g., "Take at night" or "Take with caution - may cause drowsiness")

Scenario A: Patient completes 12 chemotherapy cycles: Patient receives ginger + vitamin B6 from Cycle 2 through Cycle 12 (maximum 11 intervention cycles)
Scenario B*: Patient's chemotherapy ends before 12 cycles- If patient's treatment plan includes only 6 cycles, intervention continues through Cycle 6 only (maximum 5 intervention cycles)
Scenario C: Patient withdraws or intervention stopped early or until discontinuation If adverse effects occur or no improvement is seen, intervention stops before 12 cycles.

Adherence monitoring Strategies:
1. Pill counts
2. Adherence Checklist
3. Oncology Treatment Diary Card
4. Patient Interview/ Survey
5. MASCC Anti-emesis Tool (MAT)
6. Clinical observation by treating doctor(s)/ nurse(s)
Intervention code [1] 333520 0
Prevention
Intervention code [2] 333521 0
Treatment: Other
Description of the comparator or control
No control group
Control group
Uncontrolled

Outcomes
Primary outcome [1] 344796 0
Change in the frequency and severity of Chemotherapy-Induced Nausea and Vomiting (CINV) pre- and post-intervention, assessed as a composite outcome using the Multinational Association of Supportive Care in Cancer (MASCC Anti-emesis Tool) {MAT]
Timepoint [1] 344796 0
Baseline and after each treatment cycle to maximum of 12 treatment cycles
Secondary outcome [1] 459262 0
Recruitment rate (defined as: number of enrolled participants / number of eligible participants)
Timepoint [1] 459262 0
At the conclusion of the enrolment period (estimated 24 months from study inception)
Secondary outcome [2] 461342 0
Retention rate (defined as: number of participants who completed follow-up / number of enrolled participants)
Timepoint [2] 461342 0
At the conclusion of the follow up period
Secondary outcome [3] 461343 0
Adherence rate (defined as: number of completed intervention doses / number of prescribed doses)
Timepoint [3] 461343 0
At completion of each treatment cycle (Cycle 2 onwards); final analysis at study completion
Secondary outcome [4] 461344 0
Incidence of adverse effects related to the combined use of ginger and vitamin B6: Known/Possible Adverse Events: -Gastrointestinal discomfort such as reflux or diarrhoea (Only with high doses of Ginger which is 4grams/day, we are using maximum of 250mg/day) - Increased risk of bleeding (Only with high doses of ginger, same as mentioned above) -Peripheral neuropathy (with prolonged high-dose vitamin B6 use; however, this is minimal to no risk given the low doses used in this study: maximum 25mg/day for 5 days per treatment cycle). -Mild sedation or drowsiness/ dizziness (if doxylamine is included in the compounded capsule)
Timepoint [4] 461344 0
Assessed throughout the intervention phase (Cycle 2 onwards); documented at each treatment cycle; final analysis at study completion
Secondary outcome [5] 461345 0
Need for rescue anti-emetics (defined as: reduction in the requirement for additional oral dexamethasone and/or oral olanzapine and/or oral metoclopramide and/or oral cyclizine and /or oral haloperidol and/or oral prochlorperazine) post-intervention compared to baseline.
Timepoint [5] 461345 0
Comparison of Cycle 1 (pre-intervention baseline) with Cycle 2 onwards (post-intervention); assessed at each subsequent cycle for the duration of participant involvement
Secondary outcome [6] 461346 0
Safety: Incidence of adverse effects related to the compounded ginger, vitamin B6 and optional doxylamine.
Timepoint [6] 461346 0
At completion of each treatment cycle during the intervention phase.
Secondary outcome [7] 461347 0
Feasibility and Preliminary Efficacy for Future RCT Design: Comprehensive analysis of pilot study data including recruitment metrics, retention/adherence rates, adverse event frequency, and preliminary effect size calculation to determine if a future randomized controlled trial is warranted and to inform its design parameters (sample size, inclusion/exclusion criteria, outcome measures).
Timepoint [7] 461347 0
Final analysis at study completion
Secondary outcome [8] 462133 0
Tolerability of the compounded ginger, vitamin B6, and optional doxylamine intervention assessed through patient acceptability, feasibility of the intervention, and clinical observation
Timepoint [8] 462133 0
At start of each new treatment cycle

Eligibility
Key inclusion criteria
• Inclusion criteria:
1. Adults (> = 18 years) diagnosed with cancer commencing moderate- to high- emetogenic-risk chemotherapy, who required breakthrough anti-emetic medications and/or any episode(s) of nausea/vomiting not requiring breakthrough anti-emetic medications.
2. Eastern Co-operative Oncology Group (ECOG) Performance status 0-2
3. Able to provide informed consent.

Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
• Exclusion criteria:
1. Concurrent herbal remedies to prevent nausea/ vomiting through pre-medication history taking.
2. Pregnancy or lactation
3. Known allergy / intolerance to either ginger or vitamin B6 or both.
4. Pre-existing / Anticipatory nausea or GI disorders.
5. Hepatic or renal dysfunction (relevant to Vitamin B6 metabolism)


Study design
Purpose of the study
Prevention
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Not Applicable
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
QLD
Recruitment hospital [1] 29280 0
Ipswich Day Hospital - Ipswich
Recruitment postcode(s) [1] 45591 0
4305 - Ipswich

Funding & Sponsors
Funding source category [1] 321428 0
Charities/Societies/Foundations
Name [1] 321428 0
West Moreton hospital Foundation
Country [1] 321428 0
Australia
Primary sponsor type
Charities/Societies/Foundations
Name
West Moreton Hospital Foundation
Address
Country
Australia
Secondary sponsor category [1] 324171 0
None
Name [1] 324171 0
Address [1] 324171 0
Country [1] 324171 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 319967 0
West Moreton Hospital and Health Service
Ethics committee address [1] 319967 0
Ethics committee country [1] 319967 0
Australia
Date submitted for ethics approval [1] 319967 0
09/09/2025
Approval date [1] 319967 0
20/02/2026
Ethics approval number [1] 319967 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 148982 0
Mr Gurunath Sule
Address 148982 0
Ipswich hospital, Cancer Services, Chelmsford Avenue, Ipswich, QLD-4305
Country 148982 0
Australia
Phone 148982 0
+61 734137481
Fax 148982 0
Email 148982 0
Contact person for public queries
Name 148983 0
Gurunath Sule
Address 148983 0
Ipswich hospital, Cancer Services, Chelmsford Avenue, Ipswich,QLD-4305
Country 148983 0
Australia
Phone 148983 0
+61 734137481
Fax 148983 0
Email 148983 0
Contact person for scientific queries
Name 148984 0
Gurunath Sule
Address 148984 0
Ipswich hospital, Cancer Services, Chelmsford Avenue, Ipswich, QLD-4305
Country 148984 0
Australia
Phone 148984 0
+61 734137481
Fax 148984 0
Email 148984 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.